Quarterly report pursuant to Section 13 or 15(d)

Composition of Certain Financial Statement Captions (Tables)

v3.8.0.1
Composition of Certain Financial Statement Captions (Tables)
9 Months Ended
Sep. 30, 2017
Compositions of Certain Financial Statement Captions [Abstract]  
Composition of Certain Financial Statement Captions
(In thousands)
September 30,
2017
 
December 31,
2016
Accounts receivable, net:
 
 
 
Accounts receivable
$
291,560

 
$
256,552

Less: allowance for doubtful accounts
(57,644
)
 
(36,268
)
 
$
233,916

 
$
220,284

Inventories, net:
 
 
 
Consumable supplies
$
19,446

 
$
23,448

Finished products
22,882

 
16,143

Work in-process
4,087

 
3,896

Raw materials
6,984

 
4,686

Less: inventory reserve
(6,445
)
 
(945
)
 
$
46,954

 
$
47,228

Other current assets and prepaid expenses:
 
 
 
Taxes recoverable
17,581

 
16,187

Other receivables
12,318

 
13,021

Prepaid supplies
12,269

 
6,952

Prepaid insurance
3,276

 
3,688

Other
3,880

 
7,508

 
$
49,324

 
$
47,356

Intangible assets, net:
 
 
 
Customer relationships
$
447,699

 
$
443,560

Technologies
340,861

 
340,397

Trade names
50,520

 
50,442

Licenses
23,518

 
23,506

Covenants not to compete
16,373

 
16,348

Product registrations
10,857

 
7,641

Other
5,742

 
5,289

Less: accumulated amortization
(181,018
)
 
(123,207
)
 
$
714,552

 
$
763,976

Accrued expenses:
 
 
 
Deferred revenue
$
52,403

 
$
73,434

Employee benefits
46,237

 
43,792

Clinical trials
7,606

 
5,935

Taxes payable
4,590

 
4,430

Contingent consideration
2,011

 
259

Capital leases short-term
3,483

 
3,025

Milestone payment
9,819

 
4,865

Professional fees
2,584

 
4,035

Other
47,567

 
58,180

 
$
176,300

 
$
197,955

 
 
 
 
(In thousands)
September 30,
2017
 
December 31,
2016
Other long-term liabilities:
 
 
 
Deferred revenue
$
68,011

 
$
89,016

Line of credit
93,311

 
38,809

Contingent consideration
38,290

 
44,817

Mortgages and other debts payable
1,162

 
717

Capital leases long-term
8,435

 
7,216

Other
17,408

 
21,908

 
$
226,617

 
$
202,483

Changes in Goodwill
The following table summarizes the changes in Goodwill during the nine months ended September 30, 2017.
 
2017
(In thousands)
Balance at January 1
 
Foreign exchange and other
 
Balance at September 30th
Pharmaceuticals
 
 
 
 
 
CURNA
$
4,827

 
$

 
$
4,827

EirGen
78,358

 
9,639

 
87,997

FineTech
11,698

 

 
11,698

OPKO Chile
4,785

 
217

 
5,002

OPKO Biologics
139,784

 

 
139,784

OPKO Health Europe
6,936

 
853

 
7,789

OPKO Renal
2,069

 

 
2,069

Transition Therapeutics
3,360

 
261

 
3,621

 
 
 
 
 
 
Diagnostics
 
 
 
 
 
BioReference
401,821

 

 
401,821

OPKO Diagnostics
17,977

 

 
17,977

OPKO Lab
32,988

 

 
32,988

 
$
704,603

 
$
10,970

 
$
715,573